{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T01:31:44Z","timestamp":1777599104770,"version":"3.51.4"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12876-017-0589-6","type":"journal-article","created":{"date-parts":[[2017,2,15]],"date-time":"2017-02-15T12:02:48Z","timestamp":1487160168000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Levofloxacin or Clarithromycin-based quadruple regimens: what is the best alternative as first-line treatment for Helicobacter pylori eradication in a country with high resistance rates for both antibiotics?"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8519-6409","authenticated-orcid":false,"given":"Diogo","family":"Branquinho","sequence":"first","affiliation":[]},{"given":"Nuno","family":"Almeida","sequence":"additional","affiliation":[]},{"given":"Carlos","family":"Greg\u00f3rio","sequence":"additional","affiliation":[]},{"given":"Jos\u00e9 Eduardo Pina","family":"Cabral","sequence":"additional","affiliation":[]},{"given":"Adriano","family":"Casela","sequence":"additional","affiliation":[]},{"given":"Maria Manuel","family":"Donato","sequence":"additional","affiliation":[]},{"given":"Lu\u00eds","family":"Tom\u00e9","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2017,2,15]]},"reference":[{"key":"589_CR1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hel.12165","volume":"19.s1","author":"LH Eusebi","year":"2014","unstructured":"Eusebi LH, Zagari RM, Bazzoli F. Epidemiology of Helicobacter pylori infection. Helicobacter. 2014;19.s1:1\u20135.","journal-title":"Helicobacter"},{"issue":"s1","key":"589_CR2","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/hel.12077","volume":"18","author":"C Roubaud Baudron","year":"2013","unstructured":"Roubaud Baudron C, Franceschi F, Salles N, Gasbarrini A. Extragastric diseases and Helicobacter pylori. Helicobacter. 2013;18(s1):44\u201351.","journal-title":"Helicobacter"},{"key":"589_CR3","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1136\/gut.2009.192757","volume":"59","author":"DY Graham","year":"2010","unstructured":"Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut. 2010;59:1143\u201353.","journal-title":"Gut"},{"key":"589_CR4","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1111\/1469-0691.12701","volume":"11","author":"N Almeida","year":"2014","unstructured":"Almeida N, Rom\u00e3ozinho JM, Donato MM, Luxo C, Cardoso O, Cipriano MA, et al. Helicobacter pylori antimicrobial resistance rates in the central region of Portugal. Clin Microbiol Infect. 2014;11:1127\u201333.","journal-title":"Clin Microbiol Infect"},{"issue":"5","key":"589_CR5","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1136\/gutjnl-2012-302084","volume":"61","author":"P Malfertheiner","year":"2012","unstructured":"Malfertheiner P, Megraud F, O'Morain CA, Atherton J, Axon AT, Bazzoli F, et al. Management of Helicobacter pylori infection \u2014 the Maastricht IV \/ Florence consensus report. Gut. 2012;61(5):646\u201364.","journal-title":"Gut"},{"issue":"1","key":"589_CR6","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1136\/gutjnl-2012-302254","volume":"62","author":"F Megraud","year":"2013","unstructured":"Megraud F, Coenen S, Versporten A, Kist M, Lopez-Brea M, Hirschl AM, et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut. 2013;62(1):34\u201342.","journal-title":"Gut"},{"issue":"1","key":"589_CR7","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1365-2036.2006.02737.x","volume":"23","author":"JP Gisbert","year":"2006","unstructured":"Gisbert JP, Morena F. Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Aliment Pharmacol Ther. 2006;23(1):35\u201344.","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"589_CR8","doi-asserted-by":"crossref","first-page":"94","DOI":"10.7326\/0003-4819-144-2-200601170-00006","volume":"144","author":"V Francesco De","year":"2006","unstructured":"De Francesco V, Margiotta M, Zullo A, Hassan C, Troiani L, Burattini O, et al. Clarithromycin-resistant genotypes and eradication of Helicobacter pylori. Ann Intern Med. 2006;144(2):94\u2013100.","journal-title":"Ann Intern Med"},{"issue":"10","key":"589_CR9","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1136\/gut.2007.125658","volume":"56","author":"A Zullo","year":"2007","unstructured":"Zullo A, De Francesco V, Hassan C, Morini S, Vaira D. The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis. Gut. 2007;56(10):1353\u20137.","journal-title":"Gut"},{"issue":"11","key":"589_CR10","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1136\/gut.2010.215350","volume":"59","author":"M Romano","year":"2010","unstructured":"Romano M, Cuomo A, Gravina AG, Miranda A, Lovene MR, Tiso A, et al. Empirical Levofloxacin-containing versus Clarithromycin-containing sequential therapy for Helicobacter pylori eradication: a randomised trial. Gut. 2010;59(11):1465\u201370.","journal-title":"Gut"},{"key":"589_CR11","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1111\/j.1365-2036.2010.04297.x","volume":"31","author":"J Molina\u2010Infante","year":"2010","unstructured":"Molina\u2010Infante J, Perez\u2010Gallardo B, Fernandez\u2010Bermejo M, Hernandez\u2010Alonso M, Vinagre G, Duenas C, et al. Clinical trial: clarithromycin vs. levofloxacin in first-line triple and sequential regimens for Helicobacter pylori eradication. Aliment Pharmacol Ther. 2010;31:1077\u201384.","journal-title":"Aliment Pharmacol Ther"},{"key":"589_CR12","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ejim.2011.02.011","volume":"23","author":"Z Polat","year":"2012","unstructured":"Polat Z, Kadayifci A, Kantarcioglu M, Ozcan A, Emer O, Uygun A. Comparison of Levofloxacin-containing sequential and standard triple therapies for the eradication of Helicobacter pylori. Eur J Intern Med. 2012;23:165\u20138.","journal-title":"Eur J Intern Med"},{"key":"589_CR13","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1111\/j.1523-5378.2012.00993.x","volume":"17","author":"J Qian","year":"2012","unstructured":"Qian J, Ye F, Zhang J, Yang YM, Tu HM, Jiang Q, et al. Levofloxacin-containing Triple and Sequential Therapy or Standard Sequential Therapy as the First Line Treatment for Helicobacter pylori Eradication in China. Helicobacter. 2012;17:478\u201385.","journal-title":"Helicobacter"},{"key":"589_CR14","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.dld.2014.10.014","volume":"47","author":"H Lee","year":"2015","unstructured":"Lee H, Hong SN, Min BH, Lee JH, Rhee PL, Lee YC, et al. Comparison of efficacy and safety of Levofloxacin-containing versus standard sequential therapy in eradication of Helicobacter pylori infection in Korea. Dig Liver Dis. 2015;47:114\u20138.","journal-title":"Dig Liver Dis"},{"issue":"8","key":"589_CR15","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/phar.1614","volume":"35","author":"PB Kale\u2010Pradhan","year":"2015","unstructured":"Kale\u2010Pradhan PB, Mihaescu A, Wilhelm SM. Fluoroquinolone sequential therapy for helicobacter pylori: a meta-analysis. Pharmacotherapy. 2015;35(8):719\u201330.","journal-title":"Pharmacotherapy"},{"issue":"6","key":"589_CR16","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/hel.12062","volume":"18","author":"SD Georgopoulos","year":"2013","unstructured":"Georgopoulos SD, Xirouchakis E, Martinez\u2010Gonzalez B, Sgouras DN, Spiliadi C, Mentis AF, et al. Clinical evaluation of a ten-day regimen with esomeprazole, metronidazole, amoxicillin, and clarithromycin for the eradication of helicobacter pylori in a high clarithromycin resistance area. Helicobacter. 2013;18(6):459\u201367.","journal-title":"Helicobacter"},{"key":"589_CR17","series-title":"Gastroenterology clinics of North America","first-page":"537","volume-title":"How to effectively use bismuth quadruple therapy: the good, the bad, and the ugly","author":"DY Graham","year":"2015","unstructured":"Graham DY, Lee SY. How to effectively use bismuth quadruple therapy: the good, the bad, and the ugly, Gastroenterology clinics of North America. 2015. p. 537\u201363."},{"issue":"6","key":"589_CR18","doi-asserted-by":"crossref","first-page":"801","DOI":"10.3904\/kjim.2015.30.6.801","volume":"30","author":"SE Kim","year":"2015","unstructured":"Kim SE, Park MI, Park SJ, Moon W, Choi YJ, Cheon JH, et al. Trends in Helicobacter pylori eradication rates by first-line triple therapy and related factors in eradication therapy. Korean J Intern Med. 2015;30(6):801\u20137.","journal-title":"Korean J Intern Med"},{"key":"589_CR19","doi-asserted-by":"crossref","unstructured":"Pan KF, Zhang L, Gerhard M, Ma JL, Liu WD, Ulm K, et al. A large randomised controlled intervention trial to prevent gastric cancer by eradication of Helicobacter pylori in Linqu County, China: baseline results and factors affecting the eradication. Gut. 2015; Gutjnl.","DOI":"10.1136\/gutjnl-2015-309197"},{"issue":"2","key":"589_CR20","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.bpg.2006.11.001","volume":"21","author":"K Wolle","year":"2007","unstructured":"Wolle K, Malfertheiner P. Treatment of Helicobacter pylori. Best Pract Res Clin Gastroenterol. 2007;21(2):315\u201324.","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"7","key":"589_CR21","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/j.1365-2036.2008.03807.x","volume":"28","author":"A Villoria","year":"2008","unstructured":"Villoria A, Garcia P, Calvet X, Gisbert JP, Vergara M. Meta-analysis: high-dose proton pump inhibitors vs. standard dose in triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther. 2008;28(7):868\u201377.","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"589_CR22","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/j.1365-2036.2012.05211.x","volume":"36","author":"AG McNicholl","year":"2012","unstructured":"McNicholl AG, Linares PM, Nyssen OP, Calvet X, Gisbert JP. Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther. 2012;36(5):414\u201325.","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"589_CR23","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/j.1523-5378.2007.00556.x","volume":"12","author":"HS Choi","year":"2007","unstructured":"Choi HS, Park DI, Hwang SJ, Park JS, Kim HJ, Cho YK, et al. Double-dose, new-generation proton pump inhibitors do not improve Helicobacter pylori eradication rate. Helicobacter. 2007;12(6):638\u201342.","journal-title":"Helicobacter"},{"issue":"15","key":"589_CR24","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1517\/14656566.2015.1084503","volume":"16","author":"SD Georgopoulos","year":"2015","unstructured":"Georgopoulos SD, Papastergiou V, Karatapanis S. Treatment of Helicobacter Pylori infection: optimization strategies in a high resistance era. Expert Opin Pharmacother. 2015;16(15):2307\u201317.","journal-title":"Expert Opin Pharmacother"},{"issue":"19","key":"589_CR25","first-page":"2312","volume":"159","author":"M Lee","year":"1999","unstructured":"Lee M, Kemp JA, Canning A, Egan C, Tataronis G, Farraye FA. A randomized controlled trial of an enhanced patient compliance program for helicobacter pylori therapy. Arch Intern Med. 1999;159(19):2312\u20136.","journal-title":"Arch Intern Med"},{"issue":"2","key":"589_CR26","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1046\/j.0306-5251.2001.01531.x","volume":"53","author":"FA Al\u2010Eidan","year":"2002","unstructured":"Al\u2010Eidan FA, McElnay JC, Scott MG, McConnell JB. Management of Helicobacter pylori eradication--the influence of structured counselling and follow-up. Br J Clin Pharmacol. 2002;53(2):163\u201371.","journal-title":"Br J Clin Pharmacol"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-017-0589-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T13:50:43Z","timestamp":1719064243000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-017-0589-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,15]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["589"],"URL":"https:\/\/doi.org\/10.1186\/s12876-017-0589-6","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,15]]},"article-number":"31"}}